This innovative and proprietary suite of AI services and capabilities delivers proven speed, quality, and efficiency outcomes for sponsors and patients.
ShanghaiMay 26, 2026 /PRNewswire/ — Parexel, a leading global clinical research organization (CRO) providing clinical and consulting solutions based on professional insights to the life sciences industry, recently announced the launch of ParexelAI™. This is a human-led, innovative, and proprietary suite of AI services and capabilities that comprehensively empowers Parexel’s operations, delivering greater speed, quality, and efficiency for clients and, ultimately, patients.
ParexelAI integrates and fully leverages the company’s comprehensive AI capabilities, incorporating human oversight and transparency at every stage. With proprietary tools spanning the entire clinical development lifecycle—from early-stage clinical trials to post-market surveillance—and a diversified resource portfolio combining internal innovation, strategic partnerships, and industry-leading external capabilities, ParexelAI delivers significant outcomes for sponsors, research sites, and patients.
“ParexelAI represents the culmination of years of deep technology integration, with the core goal of helping clients deliver life-changing treatments to patients,” said Peyton Howell, CEO of Parexel. “We have a responsibility to continuously evolve by enhancing technological capabilities, deepening strategic partnerships, and innovating service models to help sponsors advance trials with greater speed and efficiency. ParexelAI is a natural extension of our corporate growth strategy and demonstrates our confidence in meeting the current and future needs of our clients.”
Empowering Operations for Greater Speed, Quality, and Efficiency
Based on quantified results, ParexelAI has achieved:
- A 50% reduction in site selection process time
- A 30% reduction in clinical study report preparation time in medical writing
- A 20% increase in efficiency for safety literature screening and pharmacovigilance case processing
With the recent acquisition of Vitrana, Parexel now offers a fully integrated pharmacovigilance (PV) platform that leverages intelligent automation and AI to accelerate end-to-end patient safety and PV processes, ensuring “first-time-right” quality outcomes and further enhancing compliance.
“Our tools are designed to automate manual tasks that hinder team efficiency, helping professionals improve quality and consistency, uncover deeper insights for clients, and continuously optimize operational excellence,” said Rob Goodwin, Chief Operating Officer of Parexel. “Supporting clients throughout the entire drug development process means they can apply the benefits of AI to all aspects of their projects, not just isolated areas.”
Leveraging Strategic Partnerships
ParexelAI’s capabilities are further enhanced through strategic collaborations with leading technology companies. These partners are evaluated and selected based on a framework prioritizing human oversight, patient safety, data integrity, security, and compliance—the same principles guiding Parexel’s internal AI applications.
- Through a strategic partnership with Paradigm Health, Parexel is transforming patient identification and trial enrollment across its network of over 800 research sites and 2,100 healthcare facilities.
- Through collaboration with Weave Bio, Parexel leverages regulatory affairs automation to reduce the writing cycle for Investigational New Drug (IND) and New Drug Application (NDA) submissions by 60%, helping sponsors make critical regulatory decisions faster than ever before.
- Parexel is the first CRO to adopt the Palantir AI platform, which serves as a core pillar of its AI-enabled clinical operations system, supporting accelerated research project delivery and high-quality outcomes.
- Additionally, Parexel utilizes partnerships with other leading technology companies to actively introduce cutting-edge innovations, committed to providing clients with a truly AI-enabled clinical development partner service.
Human-Led AI to Enhance Tangible Impact on Patients
ParexelAI places human expertise, deep scientific and regulatory knowledge, patient safety, and ethical responsibility at the core of every AI solution. By automating repetitive tasks, ParexelAI enables its global team of over 22,000 experts—including machine learning PhDs, world-leading regulatory specialists, seasoned clinical operations leaders, and technology experts—to focus on the strategic guidance, problem-solving, and high-impact challenges essential to clinical development.
“AI delivers its greatest value when it amplifies human expertise,” said Dr. Tala Fakhouri, MPH, Chief AI and Regulatory Strategy Officer at Parexel. “Our human-led model ensures quality, compliance, and patient safety at every stage of the trial lifecycle. With ParexelAI, we can apply these insights in real-time to optimize every clinical trial. Every efficiency we gain and every workflow we accelerate serves one ultimate goal: bringing treatments to patients sooner.”
For more information about ParexelAI, please visit parexel.ai.